Hormonal acne guide: why it happens and what actually treats it

Hormonal acne is the term used for acne driven primarily by androgen-mediated sebaceous gland stimulation. It is extremely common — affecting the majority of adult women with persistent acne — and it has a distinct clinical pattern and treatment approach that differs from adolescent acne. Here's the complete picture.

What makes acne "hormonal"

All acne has a hormonal component — androgens stimulate sebaceous gland activity in everyone with acne-prone skin. "Hormonal acne" is the specific subset where androgen fluctuation is the primary driver, characterized by:

1. Adult onset or persistence: New acne after age 25 in women, or acne persisting through adulthood
2. Cyclical pattern: Worsening in the week before menstruation (premenstrual flare) corresponding to the luteal phase drop in estrogen and relative androgen dominance
3. Distribution: Lower face — jawline, chin, and neck — rather than the forehead and nose typical of adolescent comedonal acne
4. Lesion type: Predominantly deep, inflamed papules and nodules (cystic); fewer surface comedones
5. Normal circulating androgens: Most women with hormonal acne have testosterone levels within the normal reference range — the issue is follicular sensitivity, not androgen excess

---

The androgen → sebum → acne pathway

Step 1: Androgen stimulation

Testosterone and its more potent metabolite DHT bind to androgen receptors in sebaceous gland cells (sebocytes). This drives:

• Sebocyte proliferation (more cells → larger gland)
• Increased sebum synthesis (more lipid production per cell)
• Ductal keratinocyte hyperproliferation (narrower follicular opening)

Step 2: IGF-1 amplification

Insulin-like growth factor 1 (IGF-1) — produced by the liver in response to growth hormone and also locally by skin cells — directly stimulates sebum production and promotes the same sebocyte hyperplasia pathway as androgens. This explains:

• Why high-glycemic diets worsen acne (insulin → elevated IGF-1)
• Why dairy products correlate with acne (dairy contains IGF-1 and bovine growth hormones)
• Why pregnancy sometimes improves and sometimes worsens acne (complex hormonal interactions)

Step 3: Comedogenesis and inflammation

Excess sebum + hyperkeratinization of the follicular duct → follicular plugging → Cutibacterium acnes (C. acnes) colonization → inflammatory cytokine release → inflamed papule, pustule, or nodule.

The deep cystic lesions of hormonal acne occur when C. acnes-mediated inflammation penetrates into the surrounding dermis, forming a nodule or pseudocyst.

---

Pattern recognition: is this hormonal acne?

Strongly suggests hormonal acne:

• Adult woman over 25 with new or persistent acne
• Jawline and chin distribution
• Cyclical premenstrual flares
• Deep, painful cystic lesions rather than surface comedones
• History of PCOS, irregular periods, or hirsutism
• Worsening with progestogen-only contraceptives or at mid-cycle

Check for underlying conditions:

• PCOS: Irregular periods, elevated androgens, ovarian cysts, hirsutism → OB/GYN evaluation
• Late-onset congenital adrenal hyperplasia (CAH): Elevated 17-hydroxyprogesterone → endocrinology
• Androgen-secreting tumors: Sudden, severe androgen excess + other virilizing signs → urgent evaluation (rare)

In most adult women with hormonal acne, circulating androgen levels are normal — the problem is end-organ (follicular) sensitivity, not androgen excess.

---

Evidence-based treatments

Spironolactone (women only)

Spironolactone is an aldosterone antagonist that also acts as an androgen receptor blocker — it prevents testosterone and DHT from binding sebaceous gland androgen receptors, reducing sebum production at the cellular level.

Dose: 50–200 mg/day; most dermatologists start at 50–100 mg and titrate based on response and side effects.

Evidence: Roberts et al. 2021 (British Journal of Dermatology) — SISTA RCT: spironolactone 100 mg/day vs. placebo in 410 women with persistent acne — significant reduction in lesion count at 24 weeks. The largest RCT for spironolactone in acne to date.

Effect: Takes 2–3 months for full effect; sebum reduction is gradual. Most effective for adult women with hormonal pattern acne; less effective for adolescent or comedonal-predominant acne.

Side effects: Menstrual irregularity (most common — dose-dependent; often resolves), breast tenderness, headache, dizziness. Hyperkalemia risk is low in healthy young women without kidney disease — Plovanich et al. (2015, JAMA Dermatology): routine potassium monitoring is not necessary in women <45 without renal disease. Not for use in men (feminizing effects; gynecomastia).

Contraindication: Pregnancy (teratogenic; requires contraception).

Oral contraceptives (OCPs)

Estrogen-containing OCPs reduce hormonal acne through two mechanisms:

1. Increased sex hormone-binding globulin (SHBG): Estrogen increases liver production of SHBG → more testosterone bound → less free (active) testosterone
2. Negative feedback on androgen production: Suppresses LH → reduces ovarian androgen production

FDA-approved OCPs for acne:

• Yaz / Yazmin (drospirenone + ethinyl estradiol) — drospirenone has anti-androgenic activity (spironolactone-like)
• Estrostep (norethindrone acetate + ethinyl estradiol)
• Ortho Tri-Cyclen (norgestimate + ethinyl estradiol)

Progestogen selection matters: Some progestins have androgenic activity and worsen acne. Levonorgestrel and norethindrone (in some formulations) can be androgenic. Anti-androgenic progestins (drospirenone, desogestrel, norgestimate) are preferred.

Timeline: 3–6 months for full effect. Acne may temporarily worsen in months 1–2 as the hormonal axis adjusts.

Combined spironolactone + OCP

For refractory hormonal acne in women, combining spironolactone with an anti-androgenic OCP provides additive benefit: OCP reduces ovarian androgen production and increases SHBG; spironolactone blocks androgen receptors at the follicular level. Both mechanisms operating simultaneously produces greater sebum reduction than either alone.

Low-dose isotretinoin (off-label)

For hormonal acne that is severe, scarring, or unresponsive to topical + hormonal treatment, low-dose isotretinoin (10–20 mg/day or 0.3 mg/kg/day) is used off-label. At low doses:

• Sebaceous gland size reduction is maintained
• Side effect burden is significantly reduced vs. standard dosing
• Monthly monitoring less intensive than standard iPLEDGE protocol (though still required)

Evidence is growing for low-dose continuous isotretinoin for adult women with hormonal acne — particularly useful when hormonal treatment is insufficient.

---

Topical treatments: what works alongside hormonal therapy

Hormonal treatments address the driver (sebum); topicals address the follicular and inflammatory consequences. Both are needed.

The anti-inflammatory + anti-comedonal stack for hormonal acne:

• Adapalene 0.1% (Differin, OTC): Normalizes follicular keratinocyte turnover; reduces comedone formation; anti-inflammatory; works on the structural cause
• Benzoyl peroxide 2.5–5%: Kills C. acnes; no resistance; reduces inflammatory lesion count; wash-off or leave-on
• Niacinamide 5–10%: Anti-inflammatory; sebum modulation; reduces redness; barrier-supportive during retinoid use
• Azelaic acid 15–20%: Dual anti-inflammatory + anti-keratinocyte proliferation; particularly good for hormonal acne with post-acne PIH in darker skin tones

Apply retinoid nightly, benzoyl peroxide AM (not same time — BP oxidizes retinoids). Niacinamide and azelaic acid flexible.

What to avoid

• Heavy, occlusive moisturizers and oils on acne-prone areas (particularly the jawline)
• Haircare products with oils or silicones that contact the jawline (pompadour-back or up-do can redirect product runoff onto acne-prone skin)
• Progestogen-only "mini-pill" OCPs — often androgenic; frequently worsen acne
• High-glycemic foods and dairy if there is consistent dietary correlation (individual variation)

---

Setting expectations

Hormonal acne responds to the right treatment but slowly:

• Topical retinoids: 8–12 weeks for meaningful improvement
• Spironolactone: 2–3 months for initial response; 4–6 months for full effect
• OCPs: 3–6 months for full hormonal axis adjustment
• Combination treatment: 6–9 months to reach maximum benefit

Cyclical premenstrual flares may persist early in treatment — this is expected and typically reduces over months of consistent treatment.

---

Looking for a hormonal acne consultation? Browse dermatology providers on MedSpot →